STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences, Inc. - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

News

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces new data highlighting the value of its IDgenetix pharmacogenomic (PGx) test in guiding medication recommendations for older adults with mental health conditions. The study shows one-third of medication recommendations were due to drug-drug interactions and lifestyle factors, emphasizing the importance of personalized medication selection in elderly patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 19, 2024. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
-
News

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces data presentations at AAD Annual Meeting showcasing improved survival in patients with cutaneous melanoma using DecisionDx-Melanoma test. The company's gene expression profile tests demonstrate effectiveness in guiding personalized care for skin cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
conferences
News

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces the largest study of its DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma, demonstrating improved predictive accuracy and personalized treatment pathways. The study highlights the test's ability to guide risk-appropriate treatment decisions, reducing overtreatment and undertreatment, based on patients' biological risk of metastasis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
-
News

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Rhea-AI Summary
Castle Biosciences (CSTL) reports a strong performance in 2023, with $220 million revenue, a 60% increase from 2022, and 70,429 test reports delivered. The company also achieved $243 million in cash, two critical publications associating with DecisionDx-Melanoma testing, and a successful conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.95%
Tags
earnings
-
News

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced study results demonstrating the superior risk stratification of DecisionDx-Melanoma in stage I melanoma patients. The study, including 5,651 patients, showed better outcomes than AJCC8 staging. Incorporating DecisionDx-Melanoma may enhance clinical decision-making for more precise information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
News

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. The company will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Access details for the webcast and phone conference call are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
-
News

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced a study in The Journal of Clinical and Aesthetic Dermatology which found that using its DecisionDx-SCC test to guide adjuvant radiation therapy (ART) decisions for patients with squamous cell carcinoma (SCC) could result in substantial Medicare healthcare savings of up to approximately $972 million annually. The study also highlighted the potential to improve patient care by providing added confidence in decisions to forgo radiation therapy when a patient’s risk of metastasis is low.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
News

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will present new data on its dermatologic gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference. The data includes real-world evidence confirming risk stratification for melanoma, identifying high-risk SCC patients, diagnostic discordance for melanocytic lesions, and gene expression differences in skin samples of inflammatory skin diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced that its COO, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. Oelschlager's extensive background and instrumental role in Castle's success have led to her recognition as a driving force in biotechnology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
none

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $25.46 as of January 14, 2025.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 697.1M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.
Stock CSTL logo
Castle Biosciences, Inc.

Nasdaq:CSTL

CSTL Rankings

#2825 Ranked by Market Cap
N/A Ranked by Dividends

CSTL Stock Data

697.10M
27.07M
3.38%
94.29%
6%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD